Skip to main content

Advertisement

SpringerLink
Log in

Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Sabarubicin (MEN 10755), a new disaccaride anthracycline, has shown greater efficacy than Doxorubicin in a large panel of preclinical models and now it is in phase II clinical trials. Its promising antitumour activity promoted considerable interest to combine Sabarubicin with other antitumour agents. Thus, the purpose of this study was to evaluate in vitro cytotoxic effects and in vivo antitumour activities produced by the combination of Sabarubicin and cisplatin (DDP).

Methods

The antitumour effect of Sabarubicin and DDP association was investigated, in vitro and in vivo, in preclinical models of lung cancer i.e.: the non-small cell lung carcinoma (NSCLC) H460 and the small-cell lung carcinoma (SCLC) GLC4 in terms of synergism, additivity or antagonism in order to establish the best schedule for the combined treatment. Further, the correlation between antitumour activity and the pharmacokinetic parameters of the studied combination was also evaluated.

Results

The drug combination in vitro was in general more cytotoxic than the single drug alone, indicating the presence of a synergistic effect in both tumour cell lines. Also, in the xenograft experiments a superior antitumoral effect was observed when Sabarubicin was combined with DDP. The antitumour efficacy of Sabarubicin (6 mg/kg q4d × 5) combined with DDP (6 mg/kg q4d × 3) greatly depended on the schedule of administration. In H460 tumour line, the sequential combination was more effective than the simultaneous administration of the two agents, although the antitumour efficacy was not dependent on the sequence of combination. On the other hand, a strong sequence-dependent effect was observed when Sabarubicin was combined with DDP in SCLC, GLC4. In particular, the highest value of LCK = 6.7 was obtained when administration of DDP followed by 24 h that of Sabarubicin. Pharmacokinetics of Sabarubicin in combination with DDP was evaluated at 6 mg/kg for both drugs with different sequential schedule. The experimental data showed no evidence for pharmacokinetics drug–drug interaction.

Conclusion

These preclinical results indicate the potential for a strong antitumour activity in lung tumours of the combination Sabarubicin and DDP. In particular, in SCLC the best response should be given by a sequence with administration of Sabarubicin followed 24 h later by that of DDP. Clinical trials based on these results are ongoing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. World Health Organization. GLOBOCAN (2000) Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0., IARC CancerBase No. 5. IARC Press, Lyon. http://www-dep.iarc.fr/globocan

  2. Green MR (2000) Advances in the management of lung cancer. Oncology 14 N.7(suppl N. 4):1–52

    Google Scholar 

  3. Wakelee H, Belani CP (2005) Optimizing first-Line treatment options for patients with advanced NSCLC. Oncologist 10:1–10

    Article  PubMed  CAS  Google Scholar 

  4. Ancuceanu RV, Istudor RV (2004) Pharmacologically active natural compounds for lung cancer. Altern Med Rev 9(4):402–419

    PubMed  Google Scholar 

  5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR (2004) American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 22(2):330–353

    Article  PubMed  Google Scholar 

  6. Tester W, Mora J (2001) Innovative treatments for advanced non-small-cell lung cancer. Expert Opin Investig Drugs 10(6):1021–1032

    Article  PubMed  CAS  Google Scholar 

  7. Rigas JR (2004) Taxane–Platinum combination in advanced non-small cell lung cancer: a review. Oncologist 9(suppl 2):16–23

    Article  PubMed  CAS  Google Scholar 

  8. Bunn PA Jr, Kelly K (2000) New combinations in the treatment of lung cancer: a time for optimism. Chest 117:138S–143S

    Article  PubMed  CAS  Google Scholar 

  9. Dy GK, Adjei AA (2002) Novel targets for lung cancer therapy: Part I. J Clin Oncol 20(12):2881–2894

    Article  PubMed  CAS  Google Scholar 

  10. Dy GK, Adjei AA (2002) Novel targets for lung cancer herapy: Part II. J Clin Oncol 20(13):3016–3028

    Article  PubMed  CAS  Google Scholar 

  11. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–584

    Article  PubMed  CAS  Google Scholar 

  12. Ohe Y, Negoro S, Matsui K, Nakagawa K, Sugiura T, Takada Y, Nishiwaki Y, Yokota S, Kawahara M, Saijo N, Fukuoka M, Ariyoshi Y (2005) Phase I–II study of Amrubicin and Cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 16:430–436

    Article  PubMed  CAS  Google Scholar 

  13. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T et al (2007) Randomised phase III trial of Carboplatin plus Etoposide vs split doses of Cisplatin plus Etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97:162–169

    Article  PubMed  CAS  Google Scholar 

  14. Martoni A, Guaraldi M, Piana E (1999) Anthracyclines in non-small-cell lung cancer: do they have a therapeutic role? Ann Oncol 10(Suppl. 5):S19–S23

    Article  PubMed  Google Scholar 

  15. Pratesi G, De Cesare M, Caserini C, Perego P, Dal Bo L, Polizzi D, Supino R, Bigioni M et al (1998) Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of Doxorubicin against human tumor xenografts. Clinical Cancer Res 4:2833–2839

    CAS  Google Scholar 

  16. Jones K (2003) MEN-10755 Menarini. Curr Opin Invest Drugs 4(12):1473–1478

    CAS  Google Scholar 

  17. Bigioni M, Salvatore C, Bullo A, Bellarosa D, Iafrate E, Animati F, Capranico G et al (2002) A comparative study of cellular and molecular pharmacology of Doxorubicin and MEN 10755, a disaccharide analogue. Biochem Pharmacol 62(1):63–70

    Article  Google Scholar 

  18. Page B, Page M, Noel C (1993) A new fluorimetric assay for cytotoxicity measurements in vitro. Int J Oncol 3:473–476

    CAS  Google Scholar 

  19. Chou T.-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enz Regul 22:27–55

    Article  CAS  Google Scholar 

  20. Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effect of Topotecan combined with various anticancer agents in human cancer cell lines. J Nat Can Inst 88(11):734–741

    Article  CAS  Google Scholar 

  21. Geran RI, Greenberg NH, Mac Donald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Reports 3:1–88

    Google Scholar 

  22. Beverly AT (1997) Anticancer drug development guide. Humana Press, Totowa

    Google Scholar 

  23. Bos AME, de Vries EGE, Dombernovsky P, Aamdal S, Uges DRA, Schrijvers D, Wanders J, Roelvink MW, Hanauske AR, Bortini S, Capriati A, Crea AEG, Vermorken JB (2001) Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemother Pharmacol 48:361–369

    Article  PubMed  CAS  Google Scholar 

  24. Morrison JC, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, Greenslade D (2000) Validation of highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharmaceut Biomed Anal 24:1–10

    Article  CAS  Google Scholar 

  25. Bettinelli M, Spezia S, Ronchi A, Minoia C (2004) Determination of Pt in biological fluids with ICP-MS: evaluation of analytical uncertainty. Atom Spectrosc 25:103–111

    CAS  Google Scholar 

  26. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, Inc, New York

  27. Gonzalez-Paz O, Polizzi D, De Cesare M, Zunino F, Bigioni M, Maggi CA, Manzini S, Pratesi G (2001) Tissue distribution, antitumor activity and in vivo apoptosis induction by MEN 10755 in nude mice. Eur J Cancer 37(3):431–437

    Article  PubMed  CAS  Google Scholar 

  28. Siddik ZH, Newell DR, Boxall FE, Harrap KR (1987) The comparative pharmacokinetics of Carboplatin and Cisplatin in mice and rats. Biochem Pharmacol 36(12):1925–1932

    Article  PubMed  CAS  Google Scholar 

  29. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185–229

    Article  PubMed  CAS  Google Scholar 

  30. Kelly K, Pan Z, Wood ME, Murphy J, Bunn PA Jr (1999) A phase I study of Paclitaxel, Etoposide, and Cisplatin in extensive stage small cell lung cancer. Clin Can Res 5:3419–3424

    CAS  Google Scholar 

  31. Voskoglou-Nomikos T, Pater JL, Seymour L (2003) Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Can Res 9:4227–4239

    Google Scholar 

  32. Gitler MS, Monks A, Sausville EA (2003) Preclinical models for defining efficacy of drug combinations: mapping the road to the clinic. Mol Cancer Ther 2:929–932

    PubMed  CAS  Google Scholar 

  33. Sausville EA, Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66(7):3351–3354

    Article  PubMed  CAS  Google Scholar 

  34. Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, Ryan AJ, Giavazzi R (2005) Potential antagonism of tubulin-binding anticancer agents in combination therapies. Clin Cancer Res 11(7):2720–2726

    Article  PubMed  CAS  Google Scholar 

  35. Troiani T, Lockerbie O, Morrow M, Ciardiello F, Eckhardt SG (2006) Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by Oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther 5(7):1883–1894

    Article  PubMed  CAS  Google Scholar 

  36. Fujimoto-Ouchi K, Tanaka Y, Tominaga T (2001) Schedule dependency of antitumor activity in combination therapy with Capecitabine/5′-deoxy-5-fluorouridine and Docetaxel in breast cancer models. Clin Cancer Res 7:1079–1086

    PubMed  CAS  Google Scholar 

  37. Takahashi N, Li WW, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, Chou TC, Scotto KW, Bertino JR (2002) Sequence-dependent synergistic cytotoxicity of Ecteinascidin-743 and Paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 62:6909–6915

    PubMed  CAS  Google Scholar 

  38. Cantero G, Pastor N, Mateos S, Campanella C, Cortes F (2006) Cisplatin-induced endoreduplication in CHO-cells: DNA damage and inhibition of topoisomerase II. Mutat Res 599(1–2):160–166

    PubMed  CAS  Google Scholar 

  39. Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, Heberer M, Reschner A (2005) Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cellular Physiol 204:522–531

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a grant from the Italian Ministry of University and Research (MIUR4800/DSPAR/1).

Author information

Authors and Affiliations

  1. Department of Pharmacology and Pharmacokinetics, Menarini Ricerche S.p.A, Via Tito Speri 10, 00040, Rome, Pomezia, Italy

    M. Bigioni, A. Benzo, C. Irrissuto, G. Lopez, B. Curatella, C. A. Maggi, S. Manzini, A. Crea & M. Binaschi

  2. Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy

    S. Caroli & F. Cubadda

Authors
  1. M. Bigioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Benzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Irrissuto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. Curatella
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. A. Maggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Manzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Crea
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Caroli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Cubadda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Binaschi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Bigioni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bigioni, M., Benzo, A., Irrissuto, C. et al. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft. Cancer Chemother Pharmacol 62, 621–629 (2008). https://doi.org/10.1007/s00280-007-0645-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0645-y

Keywords

Search

Navigation